Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic leukemia and treated according to the LALA-87 and LALA-94 trials.

Abstract

BACKGROUND:

Second malignant neoplasms are a serious complication after successful treatment of childhood acute lymphoblastic leukemia (ALL). Although treatment intensity and outcome were not comparable, with improvements in survival it is important to evaluate the rate and the type of second neoplasms in adults with ALL.

METHODS:

The data from the GET-LALA group were analyzed. A cohort of 1494 patients, aged 15 to 60 years and enrolled in 2 successive multicenter protocols between 1987 and 2002, was observed to determine the incidence of second neoplasms and associated risk factors. The median follow-up from diagnosis was 6 years.

RESULTS:

By February 2005 secondary or concomitant neoplasms were documented in 23 patients, including 9 acute myeloid leukemias (AML) or myelodysplasias (MDS), 4 non-Hodgkin lymphomas (NHL), 5 skin tumors, and 5 other solid tumors (1 lung cancer, 1 tongue carcinoma, 1 thymoma, 1 condrosarcoma, 1 histiocytosis). Neoplasms developed 0.5 to 13.8 years (median, 4.5 years) after the diagnosis of ALL. There were 22 patients in first remission and 1 was in second remission. The overall cumulative risk of secondary neoplasms was 2.1% at 5 years, 4.9% at 10 years, and 9.4% at 15 years. The cumulative risk of developing a second hematologic malignancy was 1.8% at 5 years, 2.2% at 10 years, 3.3% at 18 years; that of developing a solid tumor was 0.2% at 5 years, 2.8% at 10 years, 6.2% at 15 years. The development of secondary neoplasm was not associated with the use of any specific cytotoxic agent. However, the risk of skin tumor increased with radiation dose and transplantation (P = .01). Overall survival (OS) after the diagnosis of a second malignant neoplasm was 55% at 10 years. However, the median OS in patients developing AML/MDS was 5.7 months.

CONCLUSIONS:

The data document that adult ALL survivors are at an increased risk of later malignancy. The risk of secondary or concomitant neoplasm appeared higher than that of childhood ALL previously reported in the literature. Considering the low survival rate of this large unselected adult ALL cohort (32% at 10 years) as compared with that observed in childhood ALL, the risk of second malignancy remains underestimated. Larger series with long-term follow-up are necessary, as well as methods of screening and identification of patients at increased risk.

• Authors: Emmanuelle Tavernier, Quoc-Hung Le, Stéphane de Botton, Nathalie Dhédin, Claude-Eric Bulabois, Oumedaly Reman, Norbert Vey, Véronique Lhéritier, Hervé Dombret, Xavier Thomas
• Journal: Cancer (Cancer) Vol. 110 Issue 12 Pg. 2747-55 (Dec 15 2007) ISSN: 0008-543X [Print] United States
• PMID: 17963265 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: 2007 American Cancer Society

Topics

• Adolescent
• Adult
• Clinical Trials as Topic
• Female
• Humans
• Incidence
• Male
• Middle Aged
• Neoplasms, Second Primary (epidemiology, etiology, mortality)
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy, pathology, radiotherapy)
• Prognosis
• Retrospective Studies
• Risk Factors
• Survival Analysis